IP Library Granted Patent US 8,765,471
Granted Patent B2
US 8,765,471 · App. 13/862,773 · Granted Jul 1, 2014

Neutral protease (NP) and product by using neutral protease for tissue dissociation as well as method for the production thereof

Inventors: Manfred Kurfuerst (Moorrege, DE); Christian Raemsch (Uetersen, DE); Nicole Raemsch-Guenther (Uetersen, DE); Olaf Friedrich (Tornesch, DE); Silke Huettler (Uetersen, DE); Daniel Brandhorst (Linden, DE); Thierry Berney (Arenthon, FR); Pascal Bucher (Geneva, CH); Heide Brandhorst (Linden, DE)
Assignee: Nordmark Arzneimittel GmbH & Co. KG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,471
App. No.
13/862,773
Granted
Jul 1, 2014
Kind
B2
Abstract

The use of a neutral protease (NP) together with a collagenase consists in that a neutral protease which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production is mixed before the beginning of a tissue dissociation with a collagenase or a collagenase enzyme preparation with an individual dosage of the quantitative proportions of neutral protease and collagenase for improving the isolation results with respect to yield, viability and integrity of the cells.

Claims (23)

1. A method for isolation of islets of Langerhans from a pancreatic tissue, comprising:

mixing a separately prepared A component with a separately prepared B component in a predetermined mixing ratio of component A to component B to provide a reactant mixture, wherein the A component is a completely purified neutral protease (NP) from Clostridium histolyticum which is not contained in a collagenase enzyme preparation and which is not produced by a recombinant production, and the B component is a purified or partially purified collagenase;

combining the reactant mixture directly thereafter with the pancreatic tissue; and

isolating the islets of Langerhans.

2. The method of claim 1 , wherein the mixing ratio of component A to component B is 3% (w/w), 6% (w/w), 12% (w/w), or 24% (w/w).

3. The method of claim 2 , wherein the mixing ratio of component A to component B is 3% (w/w).

4. The method of claim 3 , wherein the pancreatic tissue is porcine pancreas.

5. The method of claim 3 , wherein the pancreatic tissue is human pancreas.

6. The method of claim 2 , wherein the mixing ratio of component A to component B is 6% (w/w).

7. The method of claim 6 , wherein the pancreatic tissue is porcine pancreas.

8. The method of claim 6 , wherein the pancreatic tissue is human pancreas.

9. The method of claim 2 , wherein the mixing ratio of component A to component B is 12% (w/w).

10. The method of claim 9 , wherein the pancreatic tissue is porcine pancreas.

11. The method of claim 9 , wherein the pancreatic tissue is human pancreas.

12. The method of claim 2 , wherein the mixing ratio of component A to component B is 24% (w/w).

13. The method of claim 12 , wherein the pancreatic tissue is porcine pancreas.

14. The method of claim 12 , wherein the pancreatic tissue is human pancreas.

15. The method of claim 2 , wherein the pancreatic tissue is porcine pancreas.

16. The method of claim 2 , wherein the pancreatic tissue is human pancreas.

17. The method of claim 1 , wherein the pancreatic tissue has been previously stored using a two-layer method with perfluoro hydrocarbons.

18. The method of claim 1 , wherein the pancreatic tissue is porcine pancreas or human pancreas.

19. The method of claim 18 , wherein the pancreatic tissue is porcine pancreas.

20. The method of claim 18 , wherein the pancreatic tissue is human pancreas.

Assignments (4)
CHANGE OF NAME Recorded Sep 28, 2021
From: NORDMARK ARZNEIMITTEL GMBH & CO. KG
To: NORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
Reel/Frame 057630/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: NORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
To: NORDMARK PHARMA GMBH
Reel/Frame 057484/0363 →
CHANGE OF NAME Recorded Sep 15, 2021
From: NORDMARK ARZNEIMITTEL GMBH & CO. KG
To: NORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
Reel/Frame 057517/0496 →
CHANGE OF NAME Recorded Sep 13, 2021
From: ORDMARK ARZNEIMITTEL HOLDING GMBH & CO. KG
To: NORDMARK PHARMA GMBH
Reel/Frame 057584/0374 →
Priority Claims (1)
DE 103 31 171 · Jul 9, 2003 · national
Continuity (2)
Division 10869313 · Jun 16, 2004
Related Publication 20130230922A1 · Sep 5, 2013